AUDUBON, PA — Globus Medical, Inc. (NYSE: GMED) has announced a major leadership transition alongside preliminary second-quarter results that show continued momentum in its core spine and enabling technologies businesses.
Effective July 18, 2025, Keith Pfeil has been appointed President and Chief Executive Officer, following the resignation of Dan Scavilla, who stepped down to pursue another opportunity after a decade with the company. Pfeil, previously Executive Vice President, COO, and CFO, has played a central role in the company’s growth strategy since joining in 2019.
“Keith brings a sharp strategic mindset and a results-oriented leadership style,” said David C. Paul, Founder and Executive Chairman of Globus Medical. “He is ideally positioned to lead Globus as we continue executing on our mission to become the preeminent musculoskeletal technology company in the world.”
Pfeil called the appointment “a privilege,” thanking both Paul and Scavilla for their trust and guidance. “I am excited to carry forward our strong culture of purpose, innovation, and teamwork that will meaningfully impact the lives of patients as we move ahead,” he said.
To support the leadership transition, Kyle Kline, who joined Globus in 2017 after nearly a decade at Deloitte, has been promoted to Chief Financial Officer. Kline most recently served as Senior Vice President of Finance and worked closely with Pfeil in his prior role. Pfeil praised Kline’s “integrity, passion, and knowledge of our business,” calling him the right choice for the CFO role.
Scavilla, who led Globus through its expansion from an implant provider to a broader musculoskeletal solutions company, said stepping down was a personal decision. “It has been an honor to lead Globus Medical and be part of this exceptional team,” he said. “I look forward to watching the company’s continued success under Keith’s leadership.”
Sales Performance Signals Growth
The company also released preliminary results for the second quarter ended June 30, 2025. Total revenue is expected to reach $745.3 million, up 18.4% from the same quarter last year. Excluding the contribution from Nevro, Inc., which was recently acquired, base business sales are projected at $650.8 million, a year-over-year increase of 3.3%, or 4.8% on a day-adjusted basis.
Pfeil credited the gains to robust performance in the U.S. spine segment, which grew approximately 7.4% on a day-adjusted basis—the strongest quarterly revenue from the segment since the 2023 merger with NuVasive. Enabling Technologies also saw sequential improvement, with growing adoption contributing to the topline.
Full-Year Outlook Reaffirmed
Globus reaffirmed its full-year 2025 guidance, maintaining its revenue forecast between $2.80 billion and $2.90 billion, and non-GAAP diluted earnings per share in the range of $3.00 to $3.30.
Final second-quarter results will be released after the market close on August 7, 2025.
The leadership changes and performance update spotlight Globus Medical’s continued evolution into a global musculoskeletal technology leader, with a deep bench of internal talent and strong market fundamentals heading into the second half of the year.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.